TGF‑β at the Crossroads: Orchestrating the Bone Metastatic Microenvironment and Shaping Therapeutic Frontiers

Bone remains one of the most hospitable-and devastating-destinations for metastatic cancer cells. At the center of this unwelcome alliance is transforming growth factor‑β (TGF‑β), a cytokine stored in the mineralized matrix and unleashed during osteoclastic bone resorption. Once activated, TGF‑β fuels a self‑reinforcing "vicious cycle": it co‑opts tumor cells to undergo epithelial‑to‑mesenchymal transition, recruits and primes osteoclasts, suppresses osteoblast function, and shapes an immunosuppressive niche that shields malignant clones. The result is a micro‑environment exquisitely tuned for tumor survival, skeletal destruction, and therapy resistance. This review traces the molecular choreography of TGF‑β signaling within the bone tumor microenvironment (TME), detailing its crosstalk with osteogenic, immune, and stromal compartments across breast, prostate, and lung cancer metastases. We synthesize pre‑clinical and clinical efforts to interrupt this pathway, ranging from ligand-neutralizing antibodies and activin receptor-like kinase 5 (ALK5) kinase inhibitors to antisense oligonucleotides and tumor-selective ligand traps-and examine why benefits observed in early trials are tempered by dose‑limiting toxicities and adaptive resistance. Beyond TGF‑β itself, we highlight parallel targets in the TME, including receptor activator of nuclear factor kappa-B ligand (RANKL)‑driven osteoclastogenesis, vascular endothelial growth factor/fibroblast growth factor (VEGF/FGF)‑mediated angiogenesis, and immune checkpoints such as PD‑1, TIM‑3, and LAG‑3, arguing that multi‑pronged combinations guided by real‑time TME profiling offer the most promising path forward. We outline pressing research priorities: mapping the spatiotemporal dynamics of TGF‑β activation, identifying predictive biomarkers for patient stratification, and engineering bone‑targeted delivery systems that preserve normal tissue repair. By decoding and disrupting the TGF‑β‑centered circuitry of bone metastasis, we can move closer to therapies that not only palliate skeletal complications but also prolong life for patients with advanced cancer.